Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Lung Research Center

Neither a doctor nor a teaching hospital

Research payments

$1,754,922

369 payments

Through program year 2025, The Lung Research Center is reported as receiving $1,754,922 in research payments, across 369 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $333,601 143
2024 Research $226,181 13
2023 Research $106,262 7
2022 Research $96,073 8
2021 Research $239,001 115
2020 Research $581,915 43
2019 Research $171,889 40

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $790,178 56 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $461,093 58 payments
  3. E.R. Squibb & Sons, L.L.C. $245,392 6 payments
  4. Biogen, Inc. $130,410 2 payments
  5. Merck Sharp & Dohme Corporation $60,572 41 payments
  6. Boehringer Ingelheim International GmbH $42,272 140 payments
  7. Celgene Corporation $15,818 1 payment
  8. Boehringer Ingelheim France S.A.S. $8,101 55 payments
  9. Boehringer Ingelheim Limited $1,087 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 $790,178 56 payments
  2. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis $195,398 2 payments
  3. PDE4 Phase III trial in IPF patients $178,461 17 payments
  4. An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis $130,410 2 payments
  5. A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) $101,975 59 payments
  6. An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) $56,497 37 payments
  7. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis $48,994 2 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $45,484 22 payments
  9. Nintedanib in PF ILD extension $43,839 4 payments
  10. A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) $36,696 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record